21 results
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
3 Nov 22
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:11pm
Third Quarter 2021–
– Initiated Phase 3 Study Evaluating Selinexor as a Maintenance Therapy in Women with Advanced or Recurrent TP53 Wild-Type … of the pivotal Phase 3 study evaluating selinexor as a maintenance therapy in women with TP53 wild-type endometrial cancer and anticipate sharing topline
8-K
EX-99.2
KPTI
Karyopharm Therapeutics Inc
8 Feb 22
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
8:16am
that can give them more time with their friends and families.”
“Women with advanced or recurrent endometrial cancer face a poor prognosis,” explains Dr
8-K
EX-99.1
lrs2e bl9bt37
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-99.1
vm7z24j
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.2
a2qq btjn
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
rd9i v53jk1
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
prhqx
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
EX-99.1
j5ccelag7zpdut8q9
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
8-K
EX-99.1
91m9p4 y43vz0ykgs
2 Mar 20
Other Events
7:05am
8-K
EX-99.1
jqpmratc6as8k
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
a432i
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am
8-K
EX-99.1
6k2eah8mtn24auz
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.2
sksis hupvqxmthi2ha
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.1
auq210 91m
3 Jul 19
Karyopharm Announces FDA Approval of XPOVIOTM(selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
1:10pm
8-K
EX-99.1
5q8h4m0zqtu1
8 Nov 18
Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
7:08am